TBIO Telesis Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TBIO

Price (delayed)

$0.32

Market cap

$9.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.64

Enterprise value

$42.27M

Codex DNA is a synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in ...

Highlights
Telesis Bio's gross margin has increased by 8% YoY
Telesis Bio's quick ratio has soared by 67% from the previous quarter but it has decreased by 16% YoY
The debt has surged by 60% year-on-year but it has declined by 31% since the previous quarter
TBIO's equity has shrunk by 99% YoY and by 99% QoQ
TBIO's EPS is down by 26% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://codexdna.com
Peers: A ILMN HBIO TMO

Key stats

What are the main financial stats of TBIO
Market
Shares outstanding
30.1M
Market cap
$9.63M
Enterprise value
$42.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
40.31
Price to sales (P/S)
0.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.54
Earnings
Revenue
$27.51M
EBIT
-$44.6M
EBITDA
-$40.49M
Free cash flow
-$36.63M
Per share
EPS
-$1.64
Free cash flow per share
-$1.23
Book value per share
$0.01
Revenue per share
$0.92
TBVPS
$2.2
Balance sheet
Total assets
$70.41M
Total liabilities
$40.87M
Debt
$34.38M
Equity
$238,000
Working capital
$22.17M
Liquidity
Debt to equity
144.45
Current ratio
3.71
Quick ratio
3.09
Net debt/EBITDA
-0.81
Margins
EBITDA margin
-147.2%
Gross margin
61.6%
Net margin
-173.5%
Operating margin
-169.2%
Efficiency
Return on assets
-51.7%
Return on equity
-237.6%
Return on invested capital
-50.2%
Return on capital employed
-71.7%
Return on sales
-162.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBIO stock price

How has the Telesis Bio stock price performed over time
Intraday
0%
1 week
3.23%
1 month
-26.94%
1 year
-86.55%
YTD
-19.8%
QTD
-27.27%

Financial performance

How have Telesis Bio's revenue and profit performed over time
Revenue
$27.51M
Gross profit
$16.95M
Operating income
-$46.54M
Net income
-$47.72M
Gross margin
61.6%
Net margin
-173.5%
The operating margin has declined by 37% since the previous quarter
The net margin has declined by 36% since the previous quarter
The operating income has contracted by 26% from the previous quarter
Telesis Bio's net income has decreased by 25% QoQ

Growth

What is Telesis Bio's growth rate over time

Valuation

What is Telesis Bio stock price valuation
P/E
N/A
P/B
40.31
P/S
0.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.54
TBIO's EPS is down by 26% since the previous quarter
TBIO's price to book (P/B) is 186% higher than its last 4 quarters average of 14.1
TBIO's equity has shrunk by 99% YoY and by 99% QoQ
TBIO's P/S is 78% below its last 4 quarters average of 1.6
TBIO's revenue is down by 8% since the previous quarter

Efficiency

How efficient is Telesis Bio business performance
Telesis Bio's ROE has plunged by 197% YoY and by 97% from the previous quarter
The return on invested capital has increased by 41% year-on-year but it has declined by 7% since the previous quarter
TBIO's return on sales is down by 36% since the previous quarter but it is up by 4.4% year-on-year
Telesis Bio's return on assets has decreased by 30% QoQ

Dividends

What is TBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBIO.

Financial health

How did Telesis Bio financials performed over time
The total assets is 72% greater than the total liabilities
The current ratio has surged by 79% since the previous quarter but it has declined by 9% year-on-year
Telesis Bio's quick ratio has soared by 67% from the previous quarter but it has decreased by 16% YoY
TBIO's equity has shrunk by 99% YoY and by 99% QoQ
The debt has surged by 60% year-on-year but it has declined by 31% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.